Search details
1.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33460574
2.
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
N Engl J Med
; 364(6): 501-13, 2011 Feb 10.
Article
in English
| MEDLINE | ID: mdl-21306237
3.
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
Target Oncol
; 18(4): 543-558, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37428347
4.
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.
Asia Pac J Clin Oncol
; 18(6): 560-569, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-34908235
5.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
J Clin Oncol
; 40(5): 449-458, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-34995105
6.
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
Invest New Drugs
; 29(6): 1449-58, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-20461441
7.
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Breast
; 59: 321-326, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34388698
8.
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Clin Breast Cancer
; 20(2): e173-e180, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31836434
9.
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
J Clin Oncol
; 32(8): 760-7, 2014 03 10.
Article
in English
| MEDLINE | ID: mdl-24297950
Results
1 -
9
de 9
1
Next >
>>